trial summary · NCT07717411
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Trial record from the TrialBase DB dataset, status RECRUITING, condition Alzheimer's Disease, sponsored by Hoffmann-La Roche. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's Disease (AD) pathology but with no cognitive or functional impairment, who are at risk for progression to mild cognitive impairment (MCI) due to AD or dementia due to AD.
Source record: https://clinicaltrials.gov/study/NCT07717411
Facts
| registry id | NCT07717411 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE3 |
| study type | INTERVENTIONAL |
| lead condition | Alzheimer's Disease |
| sponsor | Hoffmann-La Roche |
| sponsor class | INDUSTRY |
| enrollment | 1600 |
| start date | 2026-11-30 |
| primary completion | 2032-09-03 |
| completion | 2032-09-03 |
| results posted | not reported |
Conditions
- Alzheimer's Disease
Interventions
- Trontinemab
- Placebo
Countries
- Argentina
- Australia
- Canada
- China
- Taiwan
- United Kingdom
- United States
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.